- Tandem Diabetes Care Inc (NASDAQ:TNDM) posted Q1 losses of $(0.23) deeper than $(0.08) posted a year ago and missing the consensus of $(0.07).
- Sales increased 25% to $175.91 million, beating the consensus of $168.43 million.
- Worldwide pump shipments increased 11% Y/Y to 28,095.
- The gross margin remained almost unchanged at 52%.
- The company reported an operating loss of $(15.34) million, compared to $(3.24) million.
- Tandem Diabetes ended Q1 with cash and equivalents of $635.4 million.
- Guidance: Tandem expects FY22 revenues of $850 million - $865 million, reflecting Y/Y growth of 21% - 23%, versus the consensus of $846.54 million.
- Earlier, the company estimated sales of $845 million - $860 million.
- It expects gross margin to be 54% and Adjusted EBITDA margin to be 14% - 15%.
- Price Action: TNDM shares traded lower by 12.2% at $82.90 on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Tandem Diabetes' Q1 Bottom-Line Slide Deeper Into Red Despite Sales Growth
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks